Advances In Vhl Disease: Insights From Recent Research With Othon Iliopoulos, Md, Phd | Nov 2024

Advances in VHL Disease: Insights from Recent Research with Othon Iliopoulos, MD, PhD | Nov 2024

Natural History and Treatment of Hemangioblastomas in VHL | Othon Iliopoulos, MD, PhD

Clinical Management of VHL Tumors - Systemic Agents for VHL | Medical Symposium 2024

VHL 101 | Dr. Othon Iliopoulos, MD, PhD

Welireg (Belzutifan) Q&A Session with Dr. Othon Iliopoulos

The future of antibody-drug conjugates in urothelial carcinoma

Monitoring and treatment patterns in VHL disease-associated CNS hemangioblastomas .

Monitoring and treatment patterns in VHL disease-associated CNS hemangioblastomas

Von Hippel-Lindau Disease: Clinical Update and New Drug Therapy

Breakthroughs for Physicians

Hypoxia Inducible Factor-2 (HIF-2) Inhibitor Belzutifan for VHL Treatment | Family Weekend 2024

Neoadjuvant atezolizumab for advanced cutaneous squamous cell carcinoma

Current and upcoming treatment strategies for upper tract urothelial cancer

VHLA Town Hall on Belzutifan (Welireg)

Investigating production failure and out-of-specification production of CAR T-cell therapeutics

VJHemOnc – Video Journal of Hematology & HemOnc

Systemic Therapy for Von Hippel-Lindau Associated Tumors | Ramaprasad Srinivasan, MD, PhD

What are the latest biomarkers for urothelial carcinoma?

Von Hippel-Lindau Disease: Clinical Update and New Drug Therapy

Breakthroughs for Physicians

Analysis of the 5-year OS findings from the ATALANTE trial in ovarian cancer

FDA Approval of Belzutifan | Eric Jonasch, MD